Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026)

Nuvectis Pharma has reported Cash from Financing Activities over the past 6 years, most recently at $7000.0 for Q1 2026.

  • Quarterly results put Cash from Financing Activities at $7000.0 for Q1 2026, down 99.95% from a year ago — trailing twelve months through Mar 2026 was $13.6 million (down 39.4% YoY), and the annual figure for FY2025 was $29.1 million, up 149.79%.
  • Cash from Financing Activities reached $7000.0 in Q1 2026 per NVCT's latest filing, down from $166000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $15.5 million in Q1 2025 and bottomed at -$578000.0 in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was $1.5 million (2024), compared with a mean of $4.9 million.
  • The largest annual shift saw Cash from Financing Activities surged 2386.33% in 2023 before it crashed 99.95% in 2026.
  • Over 5 years, Cash from Financing Activities stood at -$131000.0 in 2022, then soared by 800.0% to $917000.0 in 2023, then skyrocketed by 317.56% to $3.8 million in 2024, then tumbled by 95.66% to $166000.0 in 2025, then crashed by 95.78% to $7000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for NVCT at $7000.0 in Q1 2026, $166000.0 in Q4 2025, and $13.1 million in Q3 2025.